Clinical trial
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With…
NCT00443690 · NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00443690 |
|---|---|
| Title | Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms, Diuresis, Renal Function, and Clinical Outcomes in Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring Intravenous Therapy |
| Acronym | REACH UP |
| Lead sponsor | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | rolofylline, Comparator: Placebo (unspecified) |
| Enrollment | 480 |
| Start date | Aug 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Mar 6, 2007 |
| Last update posted | Feb 20, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: